Over about the last 5 years, this has changed with the approval of several new agents in the front-line treatment setting, including midostaurin for patients with FLT3-mutations, gemtuzumab-ozogamicin for patients with intermediate or favorable risk karyotype and CPX-351 for patients with secondary AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.